Stamford Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative immune therapies for the treatment of cancer, particularly cutaneous and visceral cancers. Their approach emphasizes the complexity of cancer as a dynamic disease influenced by the tumor microenvironment, which consists of various cell types and molecular interactions. By remodeling this microenvironment and employing a multi-pathway and multi-target strategy, Stamford aims to enhance the effectiveness and durability of cancer treatments. Their pipeline includes several promising candidates, such as SP-002, an adenoviral vector designed to deliver Interferon-γ directly to tumors, thereby improving therapeutic outcomes while minimizing systemic toxicity.

The company is advancing multiple clinical trials, including studies on SP-002 in combination with Hedgehog Pathway Inhibitors for locally advanced basal cell carcinoma (BCC). This combination aims to address the limitations of existing treatments by targeting both the tumor and its resistant populations. Additionally, Stamford is exploring the use of SP-105, which combines SP-002 with a controlled-release COX-2 inhibitor to enhance local immune responses and counteract treatment resistance. Their SP-500 platform is also under development to tackle intratumoral heterogeneity, which often leads to treatment failure. Overall, Stamford Pharmaceuticals is committed to pioneering therapies that can significantly improve patient outcomes in oncology.

United States

We are a clinical stage oncology focused company developing novel gene therapies focused on dermatological and visceral cancers.

Stamford Pharmaceuticals

Company Details